Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA requests additional Phase III comparative study and safety data for iloperidone.

You may also be interested in...



Novartis Deal Sealed, Vanda Plays Up Injectable Potential

Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.

Novartis Deal Sealed, Vanda Plays Up Injectable Potential

Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.

Vanda’s Fanapt Approval Shows Evolution Of FDA’s Thinking

FDA's approval of Vanda's Fanapt (iloperidone) May 6 means that the bar for new atypical antipsychotic approvals may not be as high as it seemed 10 months ago, when FDA's "not approvable" letter on iloperidone requested an additional comparative trial

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel